Advertisement

Topics

Latest "PharmaVentures Limited" News Stories

18:55 EDT 22nd March 2019 | BioPortfolio

Here are the most relevant search results for "PharmaVentures Limited" found in our extensive news archives from over 250 global news sources.

More Information about PharmaVentures Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about PharmaVentures Limited for you to read. Along with our medical data and news we also list PharmaVentures Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of PharmaVentures Limited Companies for you to search.

Showing "PharmaVentures Limited" News Articles 1–25 of 261

Thursday 21st March 2019

AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference

Paris, March 21, 2019, 6.30pm AB Science Announces Acceptance of Abstract for Oral Presentation at the 2019 Muscular Dystrophy Association Conference Data Provides Further Evidence on Masitinib's Mode of Action in ALS via Modulation of the Degenerative Neuronal Microenvironment AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research,...


Wednesday 20th March 2019

Imugene’s Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx Immunotherapy Clinical Development Plan

Sydney, Australia – 20 March 2019 – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced it had received and accepted the minutes of its Pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) for its KEY-Vaxx cancer immunotherapy on 8 February 2019. Imugene Managing Director and Chief Executive Officer Leslie Cho...

Thursday 14th March 2019

Imugene Announces First Patient Dosed in the Open-Label Phase 2 Study with HER-Vaxx Cancer Vaccine for Advanced Gastric Cancer

First patient dosed in 68 patient Randomised Phase 2 HER-Vaxx cancer trial Two Eastern European sites now actively recruiting Approval imminent for trial sites in Hong Kong, Taiwan, Thailand and India SYDNEY, Australia –14 March 2019 – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced dosing of the first patient in an open-label, ra...


Tuesday 12th March 2019

AVITA Medical to Present at Cowen and Company Health Care Conference

AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that management will present at the Cowen and Company 39th Annual Health Care Conference in Boston. The presentation is being made on 13 March 2019 from 11:20 a.m. to 11:50 a.m. EDT at the Boston Marriott Copley Place. A copy of the slide presentation will be posted t...

ERS Genomics provides comment on issuance of University of California CRISPR/Cas9 patent including uses of CRISPR ‘in a cell’.

U.S. Patent No. 10,227,611 issued to Dr. Emmanuelle Charpentier, University of California and University of Vienna DUBLIN, Ireland, 12 March 2019: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a new patent...

Monday 11th March 2019

Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane

F. Hoffmann-La Roche Ltd / Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. PD-L1 (SP142) was the enrol...

Wednesday 6th March 2019

Quotient Limited to Participate in the Cowen and Company 39th Annual Health Care Conference

JERSEY, Channel Islands, March 07, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chris Lindop, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019 at 3:30 p.m. ET at the Boston Marriott Copley Place. A webcast of the presentation will...

Tuesday 5th March 2019

Kiadis Pharma Strengthens Management Team

                                                 Kiadis Pharma Strengthens Management Team Dirk de Naeyer appointed Chief Operations Officer and Martine Nolan as Head of Quality Assurance, effective March 1, 2019 Amsterdam, The Netherlands, March 5, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Eur...

Iksuda Therapeutics and Femtogenix sign license agreement - Agreement gives Iksuda access to Femtogenix’s therapeutic payloads to advance lead ADC for difficult-to-treat solid tumours

Newcastle, UK, 5th March 2019: Iksuda Therapeutics (Iksuda), the next-generation Antibody Drug Conjugate (ADC) company, today announced it has signed a licensing agreement with Femtogenix Limited (FGX), the next-generation ADC payload company. As part of this agreement, Iksuda will use FGX’s sequence-selective DNA-interactive payload molecules to progress its lead ADC towards the clinic...

Sunday 3rd March 2019

Avita Medical Announces Collaboration with COSMOTEC, an M3 Group Company, to Commercialize the RECELL® System in Japan

COSMOTEC has filed a JPMDA application for approval to market the RECELL System in Japan AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that it has collaborated with COSMOTEC, an M3 Group company, to market and distribute the RECELL® Autologous Cell Harvesting Device (RECELL® System) for the treatment of bur...

AVITA Medical Announces Temporary Interruption of Sales of Products in EU

-Sales temporarily interrupted while closing administrative and procedural open items related to EU certificates and unrelated to product performance -No impact on U.S. market AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that sales of the RECELL® Device in the EU have been temporarily ...

Friday 1st March 2019

Kiadis Pharma to present at upcoming investor conferences in March 2019

                                                   Kiadis Pharma to present at upcoming investor conferences in March 2019 Amsterdam, The Netherlands, March 1, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today ...

Thursday 28th February 2019

Walcom Group Ltd - Death of Non-Executive Director

Walcom Group Ltd - Death of Non-Executive Director PR Newswire London, February 28 28 February 2019 WALCOM GROUP LIMITED ("Walcom" or "the Company") Death of Non-Executive Director Walcom is sad t...

Tuesday 26th February 2019

Avara to Divest API Mfg. Site

PharmaVentures retained to sell the former AstraZeneca manufacturing plant in UK

Monday 25th February 2019

PharmaVentures to Sell Former AstraZeneca Manufacturing Plant in UK

OXFORD, England, Feb. 25, 2019 /PRNewswire/ -- PharmaVentures Limited is pleased to announce that it has been appointed to sell a former AstraZeneca manufacturing site in Avonmouth, near Bristol, ...

Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer.

FOR EX-US MEDICAL AND PHARMACETICAL TRADE MEDIA ONLY Biliary tract cancer or cholangiocarcinoma is rare, when patients fail first-line chemotherapy there are limited treatment options and in most cases the standard of care is palliative1,2 Etoposide toniribate is to be accelerated through a Phase III trial, with the aim of providing a potential additional treatment option in this are...

Tuesday 19th February 2019

STERIS to Participate in the Raymond James Institutional Investor Conference

DERBY, U.K.  - February 19, 2019 - STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced that it will participate in the Raymond James Institutional Investor Conference on Monday, March 4, 2019.   Michael J. Tokich, STERIS's Senior Vice President and Chief Financial Officer will present at 8:40 a.m. Eastern Time. A simultaneous webcast and re...

BioPortfolio.com - Valuation and Opportunity to Acquire BioPortfolio Limited

Dorchester, 19th February 2019:  Following the circulation of our Private Memorandum Document - "BioPortfolio Ltd - Acquisition Opportunity" last month we are forwarding further details on pricing and our proposed stages to conclude the transfer of the business to a new owner. Valuation Peter Barfoot is anticipating between two to three times annual turnover.  For the curr...

Monday 18th February 2019

Quotient Limited to Host Investor Day and Ring Closing Bell at the NASDAQ on March 4, 2019

JERSEY, Channel Islands, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company will host an Investor Day on Monday, March 4, 2019 from 1:00pm – 3:00pm ET, in New York, NY. Following the Investor Day, the Company’s Chief Executive Officer, Franz Walt, will ring the Closing Bell of the NASDAQ Stock Exchange....

RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea (OSA) in Australia, New Zealand and Southeast Asia

Glen Rock, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the treatment of sleep-related breathing disorders, is pleased to announce that it has entered into a non-binding memorandum of understanding (“MOU”) and exclusivity agreement with Impression Hea...

Recce Successfully Raises AUD$1.8 million to Advance Lead Antibiotic Program

AUD$1.8m raised via placement from sophisticated and institutional investors Strengthened balance sheet to support Lead Antibiotic Program Strong support from existing and new shareholders Sydney, Australia – 18 February 2019 – Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), is pleased to announce that it has raised approximately AUD$1.8m (before costs) fro...

Friday 15th February 2019

Kiadis Pharma Notice of Extraordinary General Meeting of Shareholders

                                                                  Amsterdam, The Netherlands, 15 February 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that it has convened an extraor...

Herantis Pharma Plc is planning a directed share issue and prepares for a contemplated secondary listing on the First North Stockholm marketplace

Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors and prepares for a contemplated secondary listing on the First North Stockholm marketplace Herantis Pharma Plc Company release 15 February 2019 at 9:00 am Not for publication or distribution, directly or indirectly, in or into Australia, South Africa, Hong Kong, Japa...

Thursday 14th February 2019

Quotient Limited to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

JERSEY, Channel Islands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that today announced that the Company’s Chief Executive Officer, Franz Walt, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at 10:00 a.m. EST at the Lotte New York Palace Hotel, in New York, NY. ...

Feedback Medical appoints radiologist and NHS England Clinical Entrepreneur Fellow as CEO

Cambridge, UK, 14 February 2019 - Feedback plc (AIM: FDBK, "Feedback", or the “Company”), the specialist medical imaging technology company, announces that its operating subsidiary, Feedback Medical Ltd, has appointed Dr Tom Oakley as its Chief Executive Officer. A qualified clinical radiologist, Dr Oakley has significant experience of successfully launching healthcare pr...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks